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Abstract
Toll-like receptors (TLRs) play a crucial role in the innate immune response. Although endo-
somal TLR7 recognizes single-stranded RNAs, their endogenous RNA ligands have not
been fully explored. Here, we report 50-tRNA half molecules as abundant activators of TLR7.
Mycobacterial infection and accompanying surface TLR activation up-regulate the expres-
sion of 50-tRNA half molecules in human monocyte-derived macrophages (HMDMs). The
abundant accumulation of 50-tRNA halves also occur in HMDM-secreted extracellular vehi-
cles (EVs); the abundance of EV-50-tRNAHisGUG half molecules is >200-fold higher than that
of the most abundant EV-microRNA (miRNA). Sequence identification of the 50-tRNA halves
using cP-RNA-seq revealed abundant and selective packaging of specific 50-tRNA half spe-
cies into EVs. The EV-50-tRNAHisGUG half was experimentally demonstrated to be delivered
into endosomes in recipient cells and to activate endosomal TLR7. Up-regulation of the 50-
tRNA half molecules was also observed in the plasma of patients infected with Mycobacte-
rium tuberculosis. These results unveil a novel tRNA-engaged pathway in the innate immune
response and assign the role of “immune activators” to 50-tRNA half molecules.
Introduction
There are many pathogenic microbes that induce a wide range of symptoms and diseases,
including Mycobacterium tuberculosis (Mtb), one of the greatest threats to humans, causing
more than 1.2 million deaths annually [1]. When a host is infected with pathogenic microbes,
it has 2 essential arms of defense to eliminate them: the innate immune system and the adap-
tive immune system [2]. In the innate immune system, Toll-like receptors (TLRs) and other
pathogen recognition receptors detect pathogen-associated molecular patterns (PAMPs) and
initiate protective responses [3,4]. Among the 10 TLRs characterized in humans, TLR1, TLR2,
TLR4, TLR5, TLR6, and TLR10 localize to the cell surface (surface TLRs), while TLR3, TLR7,
TLR8, and TLR9 localize to intracellular compartments such as endosomes (endosomal
TLRs). When TLRs recognize PAMPs, they recruit adaptor proteins, such as MyD88 and
TRIF, to initiate signal transduction pathways that culminate in the activation of transcription
factors such as NF-κB and AP-1, leading to the production of cytokines and chemokines for
host defense [5,6].
PLOS BIOLOGY







Citation: Pawar K, Shigematsu M, Sharbati S,
Kirino Y (2020) Infection-induced 50-half molecules
of tRNAHisGUG activate Toll-like receptor 7. PLoS
Biol 18(12): e3000982. https://doi.org/10.1371/
journal.pbio.3000982
Academic Editor: Mathieu JM Bertrand,
Universiteit Gent, BELGIUM
Received: August 19, 2020
Accepted: November 13, 2020
Published: December 17, 2020
Copyright: © 2020 Pawar et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The Next-Generation
Sequence libraries are publicly available from the
NCBI Sequence Read Archive (accession No.
SRR8430192, SRR8430191, and SRR8430193).
Funding: This study was supported in part by the
National Institutes of Health Grant (GM106047,
AI130496, and HL150560 to YK), American Cancer
Society Research Scholar Grant (RSG-17-059-01-
RMC, to YK), and The W.W. Smith Charitable Trust
Grant (C1608, to YK). The funders had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Endosomal TLRs are known to sense nucleic acids, which act as ligands [7,8]. Of the endo-
somal TLRs, TLR7 and TLR8 recognize single-stranded RNAs (ssRNAs), whereas TLR3 and
TLR9 recognize dsRNAs and ssDNAs, respectively. TLR7 and TLR8 are primarily expressed in
immune cells such as monocytes/macrophages, dendritic cells, neutrophils, and B cells, and
their recognition of pathogen-derived ssRNAs (e.g., viral and bacterial ssRNAs) recruits
MyD88, activates NF-κB-mediated transcription, and induces the production of interferons
and cytokines [9]. Besides pathogen-derived ssRNAs, TLR7 and TLR8 also sense host ssRNAs,
such as microRNAs (miRNAs). miRNAs can be incorporated into extracellular vehicles (EVs),
and those EV-miRNAs can reach and function as agonist of endosomal TLR7 and TLR8 in
recipient cells [10–12]. The activation of TLR7 and TLR8 by miRNAs is involved not only in
the immune response [13,14]but also in tumor growth and metastasis [15–17] and in neuronal
damage and apoptosis [10,18]. Considering that EV contains many other RNA species (e.g.,
messenger RNAs [mRNAs], transfer tRNAs [tRNAs], small nucleolar RNAs [snoRNAs],
Y-RNAs, vault RNAs, and long noncoding RNAs [lncRNAs]) [19,20], it is not surprising that
those EV-RNAs are also deliverable to endosomal TLRs and function as their ligands, though
this possibility remains unexplored.
Although tRNAs are best known as essential adapter molecules of translational machinery,
recent studies have established their role as a source of short noncoding RNAs (ncRNAs) [21–
24]. In many organisms, specific tRNA-derived ncRNAs are expressed as functional molecules
and are involved in various biological processes beyond translation. tRNA-derived ncRNAs
can be classified into 2 groups: tRNA halves and shorter tRNA-derived fragments (tRFs).
Among them, 50-tRNA halves, which comprise the region from the 50-end to the anticodon
loop of tRNAs, are one of the most abundant classes. In mammalian cells, they are generated
from angiogenin (ANG)-mediated anticodon cleavage of tRNAs [25,26] and have been shown
to regulate translation, promote stress response, promote cell proliferation, and be associated
with cancers, neurodegenerative diseases, and metabolic disorders [21–24,27–29]. 50-tRNA
halves further function as direct precursors of Piwi-interacting RNAs (piRNAs) in germ cells
[30].
Despite their demonstrated functionality, information regarding the expression profiles of
50-tRNA halves and their regulation remains elusive, in part because 50-tRNA halves are not
captured by standard RNA sequencing (RNA-seq). As a result of ANG-catalyzed biogenesis,
50-tRNA halves contain a 20,30-cyclic phosphate (cP) at their 30-end [28,31]. These cP-contain-
ing RNAs (cP-RNAs) are not ligated to a 30-adapter during cDNA amplification, and thus they
are not amplified in standard RNA-seq procedures. This limitation remains cP-RNAs, includ-
ing 50-tRNA halves, to form uncharacterized components in the transcriptomes [31]. To
resolve this issue, we developed “cP-RNA-seq” [28,32], which is able to specifically sequence
cP-RNAs and identify a comprehensive expression repertoire of 50-tRNA halves and other
cP-RNA species in human and Bombyx cultured cells and mouse tissues [28,30,33,34].
Although the expression of tRNA halves is regulated by various biological factors, such as
stresses and sex hormones [25,26,28], how bacterial infection regulates their expression is not
fully understood. Here, we report the expressional regulation and functional involvement of
50-tRNA half molecules in the infection-induced innate immune response. Infection of Myco-
bacterium bovis BCG (BCG) and surface TLR activation induced the expression of 50-tRNA
halves in human monocyte-derived macrophages (HMDMs). cP-RNA-seq-based identifica-
tion of the induced 50-tRNA halves in HMDMs and their secreted EVs revealed selective and
abundant packaging of 50-tRNA halves into EVs. We further experimentally demonstrated the
delivery of the EV-50-tRNA halves into endosomes of recipient cells and strong TLR7 activa-
tion by 50-tRNA halves. Induction of the expression and secretion of 50-tRNA halves was fur-
ther confirmed in the plasma of Mtb-infected patients, verifying that the observed phenomena
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occur not only in cell culture systems but also in actual pathological situations. Our study
unveils a novel tRNA-engaged pathway in the innate immune response and newly assigned
the role of immune activators to 50-tRNA halves.
Results
BCG infection and surface TLR activation induce the expression of 50-
tRNA halves in HMDMs
HMDMs express both surface and endosomal TLRs and have been used to study TLR path-
ways [35,36], while BCG has been used as a model bacterium for tuberculosis infection [37]. In
the present study, THP-1-derived HMDMs were infected with viable or heat-killed (HK)
BCG, and two 50-tRNA halves (50-tRNAHisGUG half and 50-tRNAGluCUC half; previously abun-
dantly detected in human breast cancer cells [28]) were quantified by tRNA half-specific Taq-
Man quantitative reverse transcription PCR (RT-qPCR) [28,30], in which a 30-adapter was
ligated to the 50-tRNA half, and then the ligation products were quantified using a TaqMan
probe targeting boundary of the adapter and the tRNA half. As shown in Fig 1A, BCG infec-
tion enhanced the expression of both of the 50-tRNA halves. The induction of 50-tRNA half
expression was independent of the viability of BCG (Fig 1A), suggesting that the induction
could result from the pathway of surface TLRs, which recognize BCG PAMPs, or from the pro-
cess of endocytosis. To examine the involvement of surface TLRs in 50-tRNA half expression,
we stimulated TLR4 and TLR2 by treating HMDMs with lipopolysaccharide (LPS) or peptido-
glycan (PGN), respectively [38,39]. Successful stimulations of the TLRs were confirmed by up-
regulation of tumor necrosis factor α (TNFα) and the macrophage inflammatory factors, MIP-
1α and MIP-1β (Fig 1B). Upon stimulation of the surface TLRs, the expression of 50-tRNA
halves was observed to be up-regulated by TaqMan RT-qPCR (Fig 1C) and northern blot (Fig
1D). Notably, the expression levels of corresponding mature tRNAs were unchanged by sur-
face TLR stimulation (Fig 1D). As described in previous studies [26,28,30,40], the production
of 50-tRNA halves did not influence the levels of mature tRNAs which are steadily maintained
by an unknown mechanism. We further analyzed primary human monocyte-derived macro-
phages (PHMDMs) differentiated from CD14+ monocytes. As in the case of HMDMs, treat-
ment of PHMDMs with LPS or PGN caused surface TLR activation (Fig 1E) and up-
regulation of 50-tRNA half expression (Fig 1F), confirming the surface TLR-induced expres-
sion of 50-tRNA halves in the primary cells of the human body.
Surface TLR-activated NF-κB up-regulates the expression of ANG mRNA
In mammalian cells, ANG cleaves the anticodon loops of tRNAs to produce tRNA halves
[25,26,28]. To confirm the involvement of ANG in the tRNA half production in LPS-treated
HMDMs, we performed siRNA-mediated knockdown (KD) of ANG expression, which
reduced the ANG mRNA levels to around 35% (S1A Fig). The ANG KD decreased the expres-
sion of 50-tRNA halves (S1B Fig), suggesting that tRNA halves are generated by ANG-medi-
ated cleavage of tRNAs in LPS-treated HMDMs. Because the expression levels of ANG mRNA
were up-regulated upon LPS or PGN treatment in HMDMs (S1C Fig) and PHMDMs (S1D
Fig), we reasoned that the transcription factors downstream of surface TLR signal transduc-
tion pathways, such as NF-κB, could induce the expression of ANG mRNA. Indeed, direct
binding of NF-κB to the region upstream of the ANG gene was suggested by chromatin immu-
noprecipitation and sequencing (ChIP-seq) data for NF-κB in lymphoblastoid B cells [41]
(S1E Fig). The potential involvement of NF-κB in ANG mRNA expression was examined by
treating HMDMs with JSH-23, an inhibitor of NF-κB [42,43], which reduced the immune
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Fig 1. Up-regulation of the expression of 50-tRNA halves by BCG infection and surface TLR activation. (A) Total RNAs from HMDMs infected with
viable or HK BCG for 0.5 or 4 h were subjected to TaqMan RT-qPCR for 50-tRNAHisGUG half (50-HisGUG) and 50-tRNAGluCUC half (50-GluCUC).
Noninfected HMDMs served as a control. The quantified 50-tRNA half levels were normalized to U6 snRNA levels. Averages of 3 experiments with SD
values are shown (�P< 0.05, ��P< 0.01, and ���P< 0.001; 2-tailed t test). (B, C) Total RNAs from HMDMs treated with LPS or PGN for 12 h were
subjected to RT-qPCR for the indicated mRNAs (B) and to TaqMan RT-qPCR for the 50-tRNA halves (C). HMDMs without treatment served as a control.
The quantified 50-tRNA half levels were normalized to the levels of U6 snRNA and GAPDH mRNA, respectively. (D) Total RNAs from HMDMs treated
with LPS or PGN were subjected to northern blot for the 50-tRNA halves and their corresponding mature tRNAs. miR-16 was analyzed as a control. (E, F)
Total RNAs from PHMDMs treated with LPS or PGN were subjected to RT-qPCR for the indicated mRNAs (E) and to TaqMan RT-qPCR for the 50-tRNA
halves (F). PHMDMs without treatment served as a control. BCG, Mycobacterium bovis BCG; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HK,
heat-killed; HMDM, human monocyte-derived macrophage; LPS, lipopolysaccharide; mRNA, messenger RNA; PGN, peptidoglycan; PHMDM, primary
human monocyte-derived macrophage; RT-qPCR, quantitative reverse transcription PCR; SD, standard deviation; TLR, Toll-like receptor; tRNA, transfer
tRNA.
https://doi.org/10.1371/journal.pbio.3000982.g001
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response as expected (S1F Fig). ANG mRNA levels were unchanged when HMDMs were
treated with NF-κB inhibitor and LPS (S1G Fig), suggesting that NF-κB-mediated transcrip-
tion up-regulates ANG mRNA, which would increase the levels of ANG protein, possibly lead-
ing to enhanced tRNA cleavage for induction of tRNA half expression by surface TLR
activation.
50-tRNA halves are massively accumulated in EVs secreted from HMDMs
To explore whether EVs secreted from HMDMs are carriers of tRNA halves, we isolated the
EVs from the culture medium of LPS-treated HMDMs by an ultracentrifugation-based
method. Western blots for the isolated EVs confirmed the presence of CD63 and Alix, proteins
known for EV accumulation [44,45], and the absence of calnexin and cytochrome c, which are
non-EV proteins [46,47] (Fig 2A). Nanoparticle tracking analysis (NTA) showed the abundant
presence of EVs from 80 to 120 nm at a high concentration (approximately 2.0 × 107 particles/
ml EV solution) (Fig 2B, S1 and S2 Movies). The isolated EVs were further observed by trans-
mission electron microscopy (Fig 2C), the results of which collectively confirmed the success-
ful isolation of HMDM EVs. The isolated EVs were subjected to TaqMan RT-qPCR for two 50-
tRNA halves, 50-tRNAHisGUG half, and 50-tRNAGluCUC half, as well as to stem-loop RT-qPCR
for 2 miRNAs, miR-21 and miR-150, which are known to abundantly accumulate in HMDM
EVs [44]. We obtained clear amplification signals from all of the 4 examined RNAs. While the
EVs treated with RNase alone yielded similar amplification signals to untreated EVs, the EVs
treated with both RNase and detergent yielded drastically reduced amplification signals (Fig
2D), confirming that the detected 50-tRNA halves and miRNAs were present inside the iso-
lated EVs and were not captured as non-EV contaminants. We further explored the absolute
amounts of the 50-tRNAHisGUG half and miR-150 in LPS-treated HMDMs and their EVs. The
calculation of the amounts was based on the standard curve from synthetic RNAs, which
showed excellent linearity between input amounts and amplification signals (S2 and S3 Figs).
The determined abundances of the 2 RNAs per μg of total HMDM RNA or per μl of EV frac-
tion are shown in Fig 2E. Although miR-150 was reported as the most abundant miRNA spe-
cies expressed in HMDMs and their EVs [44], the abundance of the 50-tRNAHisGUG half was
much more pronounced than that of miR-150: 136-fold and 215-fold higher in HMDMs and
EVs, respectively.
50-tRNA halves are produced from specific tRNA species in HMDMs and
are selectively packaged into EVs
Given the abundant accumulation of 50-tRNA halves in HMDMs and their EVs, we next iden-
tified the expression profiles of the 50-tRNA halves. Although short RNA-seq was previously
performed for HMDMs and their EVs [48,49], standard RNA-seq cannot accurately capture
50-tRNA halves because they possess a cP at their 30-end that hinders adapter ligation [28].
Instead, we employed “cP-RNA-seq,” which can selectively amplify and sequence cP-RNAs,
namely 50-tRNA halves [28,32]. The cP-RNA-seq procedure was first applied to gel-purified
short RNA fractions of HMDMs, which successfully amplified approximately 140- to 160-bp
bands (considering adapters’ lengths, inserted RNA sequences were estimated to be approxi-
mately 22 to 42 nucleotides [nt] in length) (Fig 3A). Consistent with the up-regulation of
HMDM tRNA half expression by LPS treatment (Fig 1), cP-RNA-seq amplified more abun-
dant cDNAs from the LPS-treated HMDMs than from the untreated cells (Fig 3A). In con-
trast, we failed to amplify clear cDNA bands from the RNAs of HMDM EVs by cP-RNA-seq,
possibly due to the limited amounts of EV-RNAs present. The cP-RNA-seq procedure includes
a periodate oxidation step, which might be harsh enough to damage whole RNAs if the initial
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RNA amounts are limited. Therefore, for EV-RNAs, we decided to capture all short RNA spe-
cies containing not only a cP but also a phosphate (P) or a hydroxyl group (OH) at the 30-end.
For this, EV-RNAs were first treated with T4 polynucleotide kinase (T4 PNK), which can
remove cP and P from the 30-end of RNAs, and then were subjected to the short RNA-seq pro-
cedure. This yielded abundant approximately 140- to 160-bp cDNA bands (Fig 3B), similar to
the bands obtained from cP-RNA-seq of HMDMs (Fig 3A). Interestingly, RNAs treated with a
mutant T4 PNK, which lacks 30-dephosphorylation activity [50], yielded only faint cDNA
bands, suggesting that the majority of short RNA species in EVs contain a 30-terminal cP or P
and RNAs containing a 30-OH end, such as miRNAs, are the minor species in EVs; this is con-
sistent with the experimental results shown in Fig 2E.
Fig 2. Abundant accumulation of tRNA halves in HMDM-secreted EVs. (A) Lysates from HMDMs and their secreted EVs were subjected to western blots for the
indicated EV- or non-EV proteins. (B) Isolated EVs (HMDM-EVs) were analyzed by NTA. Particle images [left; Control (PBS): negative control] and size distribution
profile (right) are shown. Representative raw video files from the NTA analyses are available in S1 and S2 Movies. (C) Transmission electron microscopic evaluation
for the isolated EVs showed small vesicles with the expected size of EVs. Four representative EV images are shown. Scale bar, 100 nm. (D) Isolated EVs were treated
with RNase A and/or Triton X-100 and then subjected to stem-loop RT-qPCR and TaqMan RT-qPCR for quantification of each of the 2 indicated miRNAs and 50-
tRNA halves, respectively. Averages of 3 experiments with SD values are shown (���P< 0.001; N.S., nonsignificant, based on 2-tailed t test). (E) Expression of the miR-
150 and 50-tRNAHisGUG half in HMDMs and their EVs was quantified by stem-loop/TaqMan RT-qPCRs, and their abundance was estimated based on the standard
curves shown in S3 Fig. Averages of 3 experiments with SD values are shown. Cyto-c, cytochrome-c; EV, extracellular vehicle; HMDM, human monocyte-derived
macrophage; miRNA, microRNA; NTA, nanoparticle tracking analysis; RT-qPCR, quantitative reverse transcription PCR; SD, standard deviation; tRNA, transfer
tRNA.
https://doi.org/10.1371/journal.pbio.3000982.g002
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Fig 3. Identification of 50-tRNA halves expressed in HMDMs and their EVs by cP-RNA-seq. (A) Gel-purified 20–45-nt RNAs from LPS-treated
HMDMs (untreated HMDMs: control) were subjected to cP-RNA-seq, which amplified 140–160-bp cDNA products (50-adapter, 55 bp; 30-adapter, 63 bp;
and thereby estimated inserted sequences, 22–42 bp). The cDNAs in the region highlighted by a line were purified and subjected to Illumina sequencing.
(B) HMDM EV-RNAs (#1 and #2: biological replicates) were treated with WT T4 PNK (PNK WT) or its mutant (PNK M) lacking 30-dephosphorylation
activity and then subjected to Illumina cDNA amplification. Amplification of 140–160-bp cDNA products was dependent on PNK WT treatment. (C)
Ratio of HMDM library versus EV library for RPM of tRNA-derived RNA reads (tRNA), ribosomal RNA-derived RNA reads (rRNA), and mRNA-derived
PLOS BIOLOGY A novel role of tRNA half molecules as activators of TLR7
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Illumina sequencing of the gel-purified approximately 140- to 160-bp cDNAs from
HMDMs and their EVs yielded approximately 35 to 44 million raw reads, of which >82% to
95% were extracted as reads with a length of 25 to 50 nt (S1 Table). tRNA-mapped reads were
enriched in EV libraries (Fig 3C); among them, the 50-tRNA halves were the most major spe-
cies, as expected (Fig 3D). While 50-tRNA halves comprised approximately 57% of tRNA-
derived reads in HMDMs, they accounted for over 93% of tRNA-derived reads in EVs, sug-
gesting that 50-tRNA halves could be selectively packaged into EVs to a greater extent than
other tRNA-derived RNAs. Considering that the human genome encodes 55 cytoplasmic
(cyto) tRNA isoacceptors with different anticodon sequences [51], the identified 50-tRNA
halves were derived from a rather focused subset of tRNAs, such as cyto tRNAValCAC, tRNAVa-
lAAC, tRNAGlyGCC, tRNAHisGUG, and tRNAGluCUC, which are in aggregates the sources of 88%
to 90% of the identified 50-tRNA halves in EVs (Fig 3E). Among the 5 major 50-tRNA halves,
the relative abundance of the 50-tRNAHisGUG half in EVs was considerably greater than that in
HMDMs, while the other four 50-tRNA halves were similarly abundant in both libraries (Fig
3E and 3F), implying preferential incorporation of the 50-tRNAHisGUG half into EVs. tRNAHis-
GUG contains an additional nucleotide at nucleotide position (np; according to the nucleotide
numbering system of tRNAs [52]) –1 of its 50-end. Our recent analyses of BT-474 human
breast cancer cells showed that the majority (approximately 60%) of cyto tRNAHisGUG contains
G–1, but a significant proportion contains U–1 or lacks the –1 nucleotide (contains G1 as a 5
0-
terminal nucleotide) [53]. As shown in Fig 3G, while the 50-tRNAHisGUG half containing G–1
was the major species in HMDMs, the majority of the 50-tRNAHisGUG halves in EVs lacked the
–1 nucleotide (G1). Similarly, while the major 3
0-terminal nucleotide was U33 for HMDM 5
0-
tRNAHisGUG halves, the majority of the EV-50-tRNAHisGUG halves contained G34 as the 3
0-end.
The 50-tRNAHisGUG half from G1 to G34 comprised approximately 80% of EV-5
0-tRNAHisGUG
halves but only 5% of HMDM 50-tRNAHisGUG halves. Inconsistency of the identified species
between HMDMs and EVs was also observed in some other major 50-tRNA half species (S4
Fig), implying that the efficiency of EV loading may not be equal for all 50-tRNA halves and
specific species could be preferentially packaged into EVs.
EV-50-tRNA halves are delivered into endosomes in recipient HMDMs
Because EV-miRNAs have been shown to be ligands for endosomal TLRs [10,11], we exam-
ined whether the abundantly identified EV-tRNA halves are delivered into endosomes in
recipient cells. We chemically tagged synthetic 50-tRNAHisGUG half or 50-tRNAGluCUC half with
fluorescein-5-thiosemicarbazide (FTSC) [54] and transfected it into HMDMs, as shown in
S5A and S5B Fig. We then isolated the EVs containing the labeled 50-tRNA halves from the
transfected cells and subsequently applied them to recipient HMDMs. As a result, we observed
the incorporation of the labeled EV-50-tRNA halves into recipient cells. Clear overlap between
the signals of the 50-tRNA halves and Rab7 (Fig 4A and 4B), an endosome marker [55], and
TLR7 (S5C and S5D Fig) confirmed the delivery of EV-tRNA halves into the endosomes of
the recipient HMDMs. These results experimentally proved that tRNA halves in HMDMs are
packaged into EVs and secreted outside of the cells, which are then delivered into the endo-
somes of recipient cells.
RNA reads (mRNA). (D) Proportion of tRNA-derived cP-RNAs classified into the indicated subgroups of tRNA-derived ncRNAs. 50- and 30-tRFs are
derived from 50- and 30-parts of tRNAs, respectively, while i-tRFs are derived from wholly internal parts of tRNAs [24]. (E) Proportion of the 50-tRNA half-
reads derived from respective cyto tRNA species. (F) Ratio of HMDM library versus EV library for RPM of the indicated 50-tRNA half species. (G)
Proportion of 50-terminal (left) and 30-terminal (right) nucleotides of the 50-tRNAHisGUG halves. cP, 20,30-cyclic phosphate; EV, extracellular vehicle;
HMDM, human monocyte-derived macrophage; LPS, lipopolysaccharide; mRNA, messenger RNA; nt, nucleotides; RNA-seq, RNA sequencing; RPM,
reads per million; T4 PNK, T4 polynucleotide kinase; tRF, tRNA-derived fragment; tRNA, transfer tRNA; WT, wild-type.
https://doi.org/10.1371/journal.pbio.3000982.g003
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50-tRNAHisGUG half activates endosomal TLR7
Given the abundant accumulation and endosome-targeted delivery of 50-tRNA halves in HMDM
EVs, we further assessed the activity of the 50-tRNA halves in stimulating ssRNA-sensing endoso-
mal TLRs (i.e., TLR7 and TLR8). As described in earlier studies [11,56], HMDMs were primed
with interferon γ and then transfected with 50-tRNAHisGUG half or 50-tRNAGluCUC half using the
cationic liposome 1,2-dioleoyloxy-3-trimethylammonium-propane (DOTAP) which mimics
EVs. As controls, a 20-nt HIV-1-derived ssRNA termed ssRNA40 (S2 Fig), known to strongly
activate endosomal TLRs [7], and its inactive mutant (ssRNA40-M), in which U is replaced with
A, were also transfected. As shown in Fig 5A, transfections of the 50-tRNAHisGUG half and
ssRNA40, a positive control, increased the production of TNFα, interleukin (IL)-1β, and IL-
12p40 mRNAs, whereas transfections of the 50-tRNAGluCUC half and ssRNA40-M, a negative
control, did not. Induction of the secretion of TNFα and IL-1β into culture medium upon the
transfection of the 50-tRNAHisGUG half, as well as ssRNA40, was further confirmed by ELISA (Fig
5B). Transfection of the 50-tRNAHisGUG half using Lipofectamine reagents did not show such
inductions (S6 Fig), confirming that the delivery of 50-tRNAHisGUG half to endosomes, not to the
cytoplasm, is necessary for the inductions. The strong activation of endosomal TLR by the
DOTAP-fused 50-tRNAHisGUG half was further observed in PHMDMs. Upon transfection of 50-
tRNAHisGUG half into PHMDMs, increased production of TNFα, IL-1β, and IL-12p40 mRNAs
(Fig 5C) and enhanced secretion of TNFα and IL-1β (Fig 5D) were observed. While the calcula-
tion of Fig 2E indicated the presence of 25 fmol of EV-50-tRNAHisGUG half per 1 ml of medium
(1 μl of EV solution was obtained from 80 μl of medium), 1.8 fmol of 50-tRNAHisGUG half per 1
ml of medium was sufficient to observe the activation of endosomal TLRs in PHMDMs (S7 Fig),
suggesting that physiologically relevant amounts of 50-tRNAHisGUG half can activate endosomal
Fig 4. Delivery of EV-50-tRNA halves into endosomes in recipient cells. EVs produced from host HMDMs containing the labeled 50-tRNAHisGUG half
(A) or 50-tRNAGluCUC half (B) were isolated and applied to recipient HMDMs. Delivery of the labeled, EV-50-tRNA half into endosomes is observed in
green. Immunofluorescence staining of Rab7 is shown in red, and DNA was counterstained with DAPI in blue. Clear co-localization of the labeled 50-
tRNA halves and Rab7 is observed in merged panels. Scale bar, 100 μm. EV, extracellular vehicle; HMDM, human monocyte-derived macrophage; tRNA,
transfer tRNA.
https://doi.org/10.1371/journal.pbio.3000982.g004
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TLR. Earlier studies have shown that modified nucleotides in tRNAs can affect endosomal TLR
activation [57,58]. In the region of the 50-tRNAHisGUG half, mature tRNAHisGUG contains the fol-
lowing 5 posttranscriptionally modified nucleotides: dihydrouridine (D) at np 16, 19, and 20;
peudouridine (C) at np 32, and queuosine (Q) at np 34 [59–61]. Among the 5 modified
Fig 5. Activation of endosomal TLR by DOTAP-fused 50-tRNAHisGUG half. (A) Using DOTAP, the synthetic 50-tRNA halves, ssRNA40 (positive control), and its
mutant (ssRNA40-M; negative control) were transfected into HMDMs. Total RNAs from the cells were subjected to RT-qPCR for the indicated mRNAs. Averages of 3
experiments with SD values are shown (��P< 0.01 and ���P< 0.001; 2-tailed t test). (B) After RNA transfection into HMDMs using DOTAP, culture medium was
subjected to ELISA for quantification of TNFα and IL-1β. (C) The experiments in (A) were performed in PHMDMs. (D) The experiments in (B) were performed in
PHMDMs. (E) The experiments in (A) were performed using 50-tRNAHisGUG half with modifications (50-HisGUG-Mod). (F) The experiments in (A) were performed
using full-length tRNAHisGUG (FL-HisGUG). DOTAP, 1,2-dioleoyloxy-3-trimethylammonium-propane; HMDM, human monocyte-derived macrophage; IL,
interleukin; mRNA, messenger RNA; PHMDM, primary human monocyte-derived macrophage; RT-qPCR, quantitative reverse transcription PCR; SD, standard
deviation; TLR, Toll-like receptor; TNFα, tumor necrosis factor α; tRNA, transfer tRNA.
https://doi.org/10.1371/journal.pbio.3000982.g005
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nucleotides, Q34 has been reported to block ANG-mediated anticodon cleavage [62] and thus
would be absent in the 50-tRNAHisGUG half. The synthetic 50-tRNAHisGUG half containing the
other 4 modified nucleotides (S2A Fig) activated endosomal TLRs as strongly as unmodified RNA
(Fig 5E), suggesting that the endogenous, modified 50-tRNAHisGUG half would have the activity.
Although mature tRNAs have been reported to be incorporated in EVs [19,20], interestingly, the
full-length tRNAHisGUG was incapable of stimulating endosomal TLR (Fig 5F) possibly due to its
rigid secondary and tertiary structures. These results suggest that shortening mature tRNAHisGUG
into less-rigid 50-half molecules by anticodon cleavage is necessary to activate endosomal TLR.
We next examined whether the 50-tRNAHisGUG half activates endosomal TLR7 and/or TLR8.
siRNA-mediated KD of TLR7 alone or simultaneous KD of TLR7 and TLR8 in HMDMs abolished
the up-regulation of TNFα, IL-1β, and IL-12p40 by DOTAP transfection of the 50-tRNAHisGUG half,



















































































































Fig 6. 50-tRNAHisGUG half activates TLR7. (A) In HMDMs, the expression of TLR7 or TLR8 was silenced by siRNAs, and
then the DOTAP-fused 50-tRNAHisGUG half or ssRNA40-M was transfected. Total RNAs from the cells were subjected to
RT-qPCR for the indicated mRNAs. Averages of 3 experiments with SD values are shown (��P< 0.01; 2-tailed t test). (B)
Lysates from 2 different TLR7 KO THP-1 cell clones (#1 and #2), as well as from WT cells, were subjected to western blots
to confirm the depletion of TLR7 expression. (C) The experiments in (A) were performed by using TLR7 KO cells
(���P< 0.001; 2-tailed t test). DOTAP, 1,2-dioleoyloxy-3-trimethylammonium-propane; HMDM, human monocyte-
derived macrophage; KO, knockout; mRNA, messenger RNA; RT-qPCR, quantitative reverse transcription PCR; SD,
standard deviation; TLR, Toll-like receptor; tRNA, transfer tRNA; WT, wild-type.
https://doi.org/10.1371/journal.pbio.3000982.g006
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half stimulates endosomal TLR7 as strongly as ssRNA40, but not TLR8. To further confirm the
involvement of TLR7 in the activity of the 50-tRNAHisGUG half, by using CRISPR/Cas9 approach, we
generated TLR7 knockout (KO) THP-1 cell lines in which TLR7 expression is completely abolished
(Fig 6B). The 50-tRNAHisGUG half did not show the activity to stimulate endosomal TLR in TLR7
KO cells (Fig 6C), confirming that the 50-tRNAHisGUG half activates endosomal TLR7.
To test whether the EV-50-tRNAHisGUG half activates TLR7, we transfected the 50-tRNAHisGUG
half, 50-tRNAGluCUC half, and ssRNA40-M (negative control) into HMDMs, and the EVs isolated
from the cells were applied to recipient HMDMs. As shown in Fig 7A, EVs isolated from
HMDMs that transiently expressed the 50-tRNAHisGUG half were able to induce immune
response. To further confirm the activity of endogenous EV-50-tRNAHisGUG halves, we utilized
antisense oligonucleotides of the 50-tRNAHisGUG half and control oligonucleotides with scram-
bled sequences. In a DOTAP transfection experiment, both oligonucleotides did not show
Fig 7. Activation of TLR7 by endogenous EV-50-tRNAHisGUG half. (A) EVs from HMDMs transfected with the
indicated 50-tRNA halves or ssRNA40-M were isolated and applied to recipient HMDMs. Total RNAs from the cells
were then subjected to RT-qPCR for the indicated mRNAs. Averages of 3 experiments with SD values are shown
(�P< 0.05, ��P< 0.01, and ���P< 0.001; 2-tailed t test). (B) The indicated synthetic RNAs, antisense oligonucleotides
of the 50-tRNAHisGUG half (AS-oligo), the control oligonucleotides with scrambled sequences (Ctrl-oligo), or a mixture
(the 50-tRNAHisGUG half was mixed with an equal amount of the oligonucleotides) were subjected to DOTAP-
mediated transfection into HMDMs, and indicated mRNAs were quantified. Averages of 3 experiments with SD values
are shown. (C) EVs from LPS-treated HMDMs were mixed with DOTAP-fused AS- or Ctrl-oligo and applied to
recipient HMDMs. Then, the indicated mRNA expression was quantified. Averages of 3 experiments with SD values
are shown. DOTAP, 1,2-dioleoyloxy-3-trimethylammonium-propane; EV, extracellular vehicle; HMDM, human
monocyte-derived macrophage; LPS, lipopolysaccharide; mRNA, messenger RNA; RT-qPCR, quantitative reverse
transcription PCR; SD, standard deviation; TLR, Toll-like receptor; tRNA, transfer tRNA.
https://doi.org/10.1371/journal.pbio.3000982.g007
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activity for endosomal TLR by themselves (Fig 7B). When mixed with an equal amount of 50-
tRNAHisGUG half, the antisense oligonucleotides impaired TLR7 activation by the 50-tRNAHisGUG
half, but the control oligonucleotides did not (Fig 7B), confirming the antisense oligonucleotides’
activity to block the 50-tRNAHisGUG half. In the experiment using the EVs isolated from
HMDMs, strikingly, the antisense oligonucleotides of the 50-tRNAHisGUG half reduced the EV-
induced up-regulation of TNFα and IL-1β by 40% to 60% (Fig 7C). Taken together, these results
confirmed that endogenous 50-tRNAHisGUG halves, which are transferred from EVs to recipient
cells, have activity to promote cytokine productions by stimulating endosomal TLR7.
Levels of circulating 50-tRNA halves are elevated in the plasma of Mtb-
infected patients
We further examined 50-tRNA half expression in human plasma samples. Plasma EVs were iso-
lated (S9A Fig) and subjected to treatments with RNase in the presence or absence of detergent.
While the plasma EVs treated with RNase alone yielded similar amplification signals to untreated
EVs, the EVs treated with both RNase and detergent yielded drastically reduced amplification sig-
nals (S9B Fig), confirming the presence of 50-tRNA halves inside the plasma EVs. Because the
quantification of 50-tRNA halves using plasma RNAs showed similar amplification patterns
with no changes in the levels of 50-tRNA halves upon RNase treatment of plasma (Fig 8A and
Fig 8. Enhanced accumulation of tRNA halves in Mtb-infected patients. (A) Human plasma sample (batch #1) was
treated with RNase A and/or Triton X-100 and then subjected to TaqMan RT-qPCR for quantification of 50-tRNA
halves. Averages of 3 experiments with SD values are shown (���P< 0.001; 2-tailed t test). (B) RNAs isolated from
plasma samples of healthy individuals (n = 8) or Mtb-infected patients (n = 6) were subjected to TaqMan RT-qPCR for
the indicated 50-tRNA halves. The quantified 50-tRNA half levels were normalized to spike-in synthetic mouse piR-3
levels. Mtb, Mycobacterium tuberculosis; RT-qPCR, quantitative reverse transcription PCR; SD, standard deviation;
tRNA, transfer tRNA.
https://doi.org/10.1371/journal.pbio.3000982.g008
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S9C Fig), the detected 50-tRNA halves in plasma samples were expected to be mostly present
inside plasma EVs. We then quantified the 50-tRNA haves in the plasma samples from healthy
individuals or Mtb-infected patients. Because the expression of tRNA halves can be affected by
sex hormones [28] and aging [34], we limited the examined individuals to males aged 30 to 35
years. During RNA extraction, a synthetic mouse piRNA was added as a spike-in control, and its
abundance was used for normalization. As shown in Fig 8B, the expression levels of 2 examined
50-tRNA halves were markedly enhanced in Mtb-infected patients compared to healthy individu-
als. The 50-tRNAHisGUG half in particular was highly elevated at approximately 10-fold higher in
Mtb-infected patients than in control individuals. These results suggest that the up-regulation
and secretion of 50-tRNA halves upon infection are not limited to cell culture settings but also
occur in actual pathological situations in pathogenic microbe-infected patients.
Discussion
Here, we identified a novel role of 50-tRNA halves as activators of TLR7. Both BCG infection
and PAMP-mediated surface TLR activation induced the expression of 50-tRNA halves in
HMDMs. Considering the results of earlier studies on the function of 50-tRNA halves in the
stress response, translation, and cell proliferation [28,63–65], infection-induced 50-tRNA
halves could function in various biological processes inside macrophages. In the present study,
we focused on the secretion of 50-tRNA halves into EVs and their role as stimulators of endo-
somal TLRs in recipient cells. Strikingly, our analyses revealed the abundant accumulation of
50-tRNA halves in HMDM-secreted EVs and their delivery to endosomes in recipient cells for
the activation of TLR7. We propose that infection-induced 50-tRNA halves function as
“immune activators” by being delivered to endosomes in surrounding cells via EV-mediated
cell–cell communication and by activating TLR7 (Fig 9).
Fig 9. A proposed model for 50-tRNA half-mediated immune response. (A) Surface TLR stimulation culminates in activation of NF-κB,
leading to up-regulation of ANG, which cleaves the anticodon loops of tRNAs. The resultant 50-tRNA halves are secreted by being packaged into
EVs and function as signaling molecules. (B) EV-50-tRNA halves are delivered into endosomes in recipient cells and activate TLR7, which
promote the immune response. ANG, angiogenin; EV, extracellular vehicle; TLR, Toll-like receptor; tRNA, transfer tRNA.
https://doi.org/10.1371/journal.pbio.3000982.g009
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Previous studies have shown that stress stimuli and sex hormone signaling pathways induce
ANG-catalyzed cleavage of the anticodon loop of tRNAs, leading to the expression of tRNA
halves termed tRNA-derived stress-induced RNAs (tiRNAs) and sex hormone-dependent
tRNA-derived RNAs (SHOT-RNAs), respectively [25,26,28]. In tiRNA biogenesis, tRNA
cleavage is triggered by decreased levels of RNH1, an ANG inhibitor, which increase ANG
availability for tRNA cleavage [66]. Although the mechanism of SHOT-RNA biogenesis is
unknown, estrogen or androgen receptors, functioning as transcription factors, might regulate
the expression of ANG and/or RNH1. In the case of infection-induced tRNA halves, our analy-
ses revealed that TLR-activated NF-κB up-regulates the expression levels of ANG mRNA,
potentially leading to enhanced levels of ANG protein available for tRNA cleavage. If this is the
mechanism behind tRNA half production, because not only surface TLR pathways but also the
TLR7 pathway culminates in NF-κB activation, there could be a feed-forward loop in which
TLR7 activation by 50-tRNA halves induces the expression of 50-tRNA halves for further activa-
tion of TLR7. In addition, because dysregulation of NF-κB is linked to various diseases, such
as cancers and inflammatory and autoimmune diseases [67–69], the potential regulation of
tRNA half production by NF-κB suggests the involvement of tRNA halves in such diseases.
By using cP-RNA-seq, we identified the complete expression repertories of 50-tRNA halves
in HMDMs and their secreted EVs, revealing that only specific tRNA species serve as major
substrates for infection-induced tRNA half expression. The molecular mechanism underlying
the anticodon loop cleavage of specific tRNA species remains unknown. Because major
substrate tRNAs such as cyto tRNAValCAC, tRNAValAAC, tRNAGlyGCC, tRNAHisGUG, and
tRNAGluCUC were also identified as major sources of SHOT-RNAs in human breast cancer
cells [28], those tRNAs may be universally susceptible to ANG cleavage, or the molecular
factors determining the susceptibility of tRNAs to anticodon cleavage, such as tRNA modifica-
tions, may be regulated similarly between the biogenesis of sex hormone–and infection-
induced tRNA halves. The difference in the expression profiles of 50-tRNA halves between
HMDMs and their secreted EVs suggests selective packaging of 50-tRNA halves into EVs.
Selective packaging of the 50-tRNAHisGUG half into EVs is intriguing as this half is highly active
in TLR7 stimulation. Although the mechanism of EV RNA content selection is unknown,
biased EV incorporation has been also shown for miRNAs [70–72] and tRFs [73,74]. Because
Y-box protein 1 (YBX1) has been reported to interact with 50-tRNA halves [64] and has been
implicated in the sorting of miRNAs for packaging into EVs [72], such RNA-binding proteins
could be involved in the selective packaging of 50-tRNA halves. Among the cellular 50-tRNAHis-
GUG half species, only a specific 50-tRNAHisGUG half, from G1 to G34, is preferentially packaged
into EVs. Specific sequences and/or secondary/tertiary structures may contribute to preferen-
tial binding to RNA-binding proteins responsible for EV packaging. Indeed, in the case of
miRNAs, specific 30-terminal sequences are required to interact with heterogeneous nuclear
ribonucleoprotein A2/B1 for preferential incorporation into EVs [70].
One of the most remarkable characteristics of 50-tRNA halves is their abundance. Although
miR-150 was identified as one of the most abundant miRNAs in HMDMs and their EVs [44],
the present quantification revealed the abundance of the 50-tRNAHisGUG half in HMDMs and
EVs to be over 130-fold and 210-fold higher, respectively. Although miRNAs have been shown
to function as ligands for TLR7, considering ligand–receptor interactions, 50-tRNA halves with
much more abundance could be more efficient, superior TLR ligands than miRNAs. Given
that T4 PNK treatment greatly enhanced amounts of EV-cDNAs during our sequencing pro-
cedure, it is predicted that EV-short ncRNA species are mostly 30-P- or cP-containing RNAs,
such as 50-tRNA halves, and that 30-OH-containing RNAs, such as miRNAs, are minor species.
While studies on EVs have established the role of EV-RNAs as cell–cell communication agents
[75], most current studies rely on standard RNA-seq, which cannot capture the 30-P or cP-
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containing RNAs that account for the majority of short RNA species in EVs. Our results sug-
gest the necessity of shedding light on these previously unrecognized RNAs by pretreating
EV-RNA fractions with T4 PNK in sequencing studies. Giraldez and colleagues revealed previ-
ously unexplored mRNA and lncRNA fragments by phosphor-RNA-seq whose procedure
includes T4 PNK treatment [76].
Another striking feature of the 50-tRNAHisGUG half is its ability to strongly activate TLR7,
but not TLR8. This selective activity for TLR7 might result from the high sensitivity of TLR7 to
GU-rich ssRNAs, such as the 50-tRNAHisGUG half, while TLR8 senses AU-rich ssRNAs [77].
The activation of TLR7 by the 50-tRNAHisGUG half is as high as that by SSRNA40, suggesting
the role of the 50-tRNAHisGUG half as an endogenous ligand for TLR7 with the full capacity to
produce an immune response. On the other hand, the 50-tRNAGluCUC half did not activate
TLR7. Because the 50-tRNAGluCUC half and the 50-tRNAHisGUG half were similarly delivered to
recipient endosomes in our delivery experiments, the inactivity of the 50-tRNAGluCUC half is
probably due to its inefficient binding to TLR7. The lack of 30-terminal GU-rich sequences
may be one of the reasons for the inefficient activity of 50-tRNAGluCUC toward TLR7 as previ-
ous study showed significance of 30-terminal GU sequences in let-7 miRNA for TLR7 activa-
tion [10]. Intriguingly, unlike the 50-tRNAHisGUG half, the full-length tRNAHisGUG is incapable
of activating TLR7, suggesting the cruciality of tRNA cleavage and production of tRNA half
molecules to yield active ligands for TLR7.
Finally, we showed the elevation of 50-tRNA half levels in the plasma of Mtb-infected
patients, demonstrating the expressional induction and secretion of 50-tRNA halves in actual
pathological situations. Because up-regulation of 50-tRNA half expression has been reported
upon infection with respiratory syncytial virus [78,79], Rickettsia [80], and hepatitis B and C
viruses [81], induction of 50-tRNA halves could be a universal phenomenon among infectious
diseases. Considering the expressional differences and the demonstrated roles of 50-tRNA
halves in the innate immune response, further characterization of 50-tRNA halves may lead to
the use of 50-tRNA halves as potential target candidates for future therapeutic applications
and/or circulating biomarkers for noninvasive testing to estimate the severity of infectious dis-
eases and the status of the immune response.
Materials and methods
Ethical approval
The Office of Human Research (OHR) of Thomas Jefferson University (TJU) approved our
use of patient samples without private information in accordance with all federal, institutional,
and ethical guidelines (#OHR-19: Expressions of noncoding RNAs in human plasma and
serum samples). We obtained the plasma samples from a company BioIVT (Westbury, New
York, United States of America) without receiving patients’ information.
Cell culture, BCG infection, PAMP treatment, and NF-κB inhibition
THP-1 human acute monocytic leukemia cells (American Type Culture Collection, Manassas,
Virginia, USA) were cultured in RPMI 1640 medium (Corning, Corning, New York, USA)
and differentiated into HMDMs using phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich,
St. Louis, Missouri, USA) as described previously [82,83]. Human CD14+ monocytes (Preci-
sion for Medicine, New Jersey, USA) were cultured in Gibco SFM medium (Thermo Fisher
Scientific, Waltham, Massachusetts, USA) and differentiated into PHMDMs using macro-
phage colony-stimulating factor (M-CSF; Tonbo Biosciences, San Diego, California, USA) as
described previously [84]. HMDMs were infected with viable or HK M. bovis BCG (DSMZ,
Braunschweig, Germany) as described previously [82,83]. Zero viability of HK-BCG was
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confirmed by spading its suspension on Middlebrook 7H11 agar plates supplemented with
OADC and confirming the absence of colonies in at least 3 weeks. For activation of surface
TLRs, HMDMs and PHMDMs were cultured with medium containing 100 ng/ml of LPS from
Escherichia coli O111:B4 (Sigma-Aldrich) or PGN from Bacillus subtilis (Sigma-Aldrich) for 12
h. For inhibition of NF-κB, HMDMs were treated with 40 μM of JSH-23 (Sigma-Aldrich) for
24 h.
EV isolation
EVs were isolated from the culture medium of LPS-treated HMDMs according to an ultracen-
trifugation-based method described previously [44]. In brief, dead cells and cell debris in the
culture medium were removed by successive centrifugation at 300 g for 10 min, 2,000 g for 10
min, and 10,000 g for 30 min. The supernatant was then ultracentrifuged using Sorvall WX
+ Ultracentrifuge Series (Thermo Fisher Scientific) at 110,000 g for 2 h. The pellet was washed
with PBS and ultracentrifuged again at 110,000 g for 2 h to eliminate contaminant proteins.
The final pellet was collected as the EV fraction. The data regarding EV isolation and charac-
terization are available in EV-TRACK database (EV-TRACK ID: EV190062) [85]. To confirm
the presence of EV-RNAs, the isolated EVs were incubated with PureLink RNase A (200 ng/μl,
Thermo Fisher Scientific) with or without 0.1% Triton X-100 at 37˚C for 30 min.
NTA and transmission electron microscopy
Size distributions of the isolated EVs were analyzed by NTA using NanoSight NS300 (Malvern
Analytical, Malvern, United Kingdom), as described previously [86], at the Flow Cytometry
Facility of the Sidney Kimmel Cancer Center at TJU. The isolated EVs were further visualized
by transmission electron microscopy (JEOL, Akishima, Tokyo, Japan) at the Centralized
Research Facilities at Drexel University.
Quantification of RNAs by TaqMan RT-qPCR, stem-loop RT-qPCR, and
standard RT-qPCR
Total RNA from the cells and EVs was isolated using TRIsure (Bioline, Swedesboro, New Jer-
sey, USA). TaqMan RT-qPCR for specific quantification of 50-tRNA halves was performed
according to our previously described tRNA half quantification method [28]. Briefly, to
remove cP from 50-tRNA halves, total RNA was treated with T4 PNK, followed by ligation to a
30-RNA adapter by T4 RNA ligase. Ligated RNA was then subjected to TaqMan RT-qPCR
using the One Step PrimeScript RT-PCR Kit (Takara Bio, Kusatsu, Shiga, Japan), 200 nM of a
TaqMan probe targeting the boundary of the target RNA and the 30-adapter, and forward and
reverse primers. The TaqMan probe and primer sequences are shown in S2 Table. Stem-loop
RT-qPCR for quantification of miRNAs and piRNAs was performed as previously described
[87,88]. In brief, total RNA was treated with DNase I (Promega, Madison, Wisconsin, USA)
and subjected to reverse transcription using SuperScript III reverse transcriptase (Thermo
Fisher Scientific) and a stem-loop reverse primer. The synthesized cDNAs were then subjected
to PCR using SsoFast Evagreen Supermix (Bio-Rad, Hercules, California, USA) and forward
and reverse primers. Sequences of the primers used are shown in S3 Table. Standard RT-
qPCR was used for quantification of mRNAs. Briefly, DNase I-treated total RNA was subjected
to reverse transcription using RevertAid Reverse Transcriptase (Thermo Fisher Scientific) and
a reverse primer. The synthesized cDNAs were then subjected to PCR using 2×qPCR Master
Mix (Bioland Scientific, Paramount, California, USA) and forward and reverse primers.
Sequences of the primers used are shown in S4 Table.
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Northern blot
Northern blot was performed as previously described [28] with the following antisense probes:
50-tRNAHisGUG half, 50-CAGAGTACTAACCACTATACGATCACGGC-30; 50-tRNAGluCUC
half, 50-GCGCCGAATCCTAACCACT-30; and miR-16, 50-GCCAATATTTACGTGCTGC
TA-30.
Western blot
Western blot was performed as described previously [87]. Lysates of HMDMs or their EVs
were prepared in RIPA buffer supplemented with cOmplete Protease Inhibitor Cocktail
(Roche, Basel, Switzerland). Anti-Alix (1A12, Santa Cruz Biotechnology, Dallas, Texas, USA),
anti-CD63 (Santa Cruz Biotechnology), anti-Calnexin (AF18, Santa Cruz Biotechnology),
anti-cytochrome c (A-8, Santa Cruz Biotechnology), and anti-TLR7 (4F4, sc-57463, Santa
Cruz Biotechnology) were used as primary antibodies.
cP-RNA-seq and bioinformatics
For cP-RNA-seq, 25–50-nt RNAs were gel-purified from the total RNA of LPS-treated
HMDMs and subjected to the cP-RNA-seq procedure as previously described [28,30,32–34].
For EV-50-tRNA half sequencing, EV-RNA was first treated with T4 PNK to remove cP from
the 50-tRNA halves, followed by adapter ligation and cDNA amplification using the TruSeq
Small RNA Sample Prep Kit (Illumina, San Diego, California, USA). The amplified cDNAs
were gel-purified and sequenced using the Illumina NextSeq 500 system at the MetaOmics
Core Facility of the Sidney Kimmel Cancer Center at TJU. The sequence libraries contain
approximately 35 to 44 million raw reads (S1 Table) and are publicly available from the NCBI
Sequence Read Archive (accession no. SRR8430192, SRR8430191, and SRR8430193). Bioinfor-
matic analyses were performed as described previously [33,34]. Reads were mapped to 471
mature cyto tRNAs obtained from GtRNAdb [51], and then to mature rRNAs, to mRNAs of
RefSeq with NM-staring accession numbers (NM is an accession prefix of known RefSeq), to
the mitochondrial genome (GenBank: CM001971.1 sequence plus 22 mitochondrial tRNA
sequences), and to the whole genome (GRCh37/hg19).
In vitro RNA synthesis
The synthetic RNAs used in this study are shown in S5 Table. While antisense oligonucleo-
tides, miRNAs, and a piRNA (spike-in) were synthesized by Integrated DNA Technologies, 50-
tRNA halves, FL-tRNAHisGUG, and ssRNA40 were synthesized by an in vitro reaction as
described previously [53]. dsDNA templates were synthesized using PrimeSTAR GXL DNA
Polymerase (Takara Bio) and the primers shown in S6 Table. The templates were then sub-
jected to an in vitro transcription reaction with T7 RNA polymerase (New England Biolabs,
Ipswich, Massachusetts, USA) at 37˚C for 4 h. For 50-tRNAGluCUC half production, the in vitro
synthesized RNA contained the ribozyme sequence to generate a mature 50-end as described
previously [89], so the reaction mixture was further incubated for 3 cycles at 90˚C for 2.5 min
and 37˚C for 15 min, allowing the ribozyme reaction. The synthesized RNAs were then gel-
purified using denaturing PAGE with single-nucleotide resolution, and the quality of the gel-
purified RNAs was confirmed by denaturing PAGE as shown in S2B Fig. For FL-tRNAHisGUG,
we performed annealing by incubating it in the annealing buffer consisting of 50 mM Tris-
HCl (pH 8) and 100 mM MgCl2 at 70˚C for 3 min, followed by incubation at 37˚C for 20 min.
Low Molecular Weight Marker 10 to 100 nt (Affymetrix, Santa Clara, California, USA) was
used as a marker in the denaturing PAGE.
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Fluorescent labeling of 50-tRNA halves and their EV-mediated delivery to
cells
The synthetic 50-tRNAHisGUG half and 50-tRNAGluCUC half were fluorescent-labeled at their 30-
end based on a previously described method [54]. In brief, synthetic RNAs were incubated in
100 mM NaOAc (pH 5.2) and 100 μM NaIO4 at room temperature for 90 min, followed by
ethanol precipitation. Then the pellet was dissolved in a solution containing 1.5 mM FTSC
(Cayman Chemical, Ann Arbor, Michigan, USA) and 100 mM NaOAc (pH 5.2), followed by
overnight incubation at 4˚C. After ethanol precipitation, the labeled RNAs were subjected to
Centri-Spin 10 (Princeton Separations, Adelphia, New Jersey, USA) purification to remove
unreacted FTSC. Then, 80 pmol of the labeled RNA was transfected into HMDMs using
RNAiMAX (Thermo Fisher Scientific). After 24 h, the cells were washed with PBS and further
incubated for 12 h with LPS, and the cell culture medium was subjected to EV isolation as
described above. The isolated EV fraction was then added to HMDMs, followed by incubation
for 6 h, and visualization of the labeled 50-tRNA halves with Rab7 and TLR7 by confocal
microscopy as described below.
Immunofluorescence staining and confocal microscopy
Immunofluorescence staining was performed as described previously [87] using anti-Rab7
(diluted 1:100, Cell Signaling Technology, Danvers, Massachusetts, USA), anti-TLR7 (diluted
1:500, Novus Biologicals, Littleton, Colorado, USA), and Alexa Fluor 488 goat anti-rabbit IgG
(diluted 1:2000, Thermo Fisher Scientific) as primary and secondary antibodies, respectively.
After DNA counterstaining with ProLong Gold Antifade Reagent with DAPI (Thermo Fisher
Scientific), images were acquired using a Nikon Eclipse Ti-U confocal microscope (Melville,
New York, USA) at the Bioimaging Facility of the Sidney Kimmel Cancer Center at TJU.
DOTAP-mediated RNA delivery to endosomes
To deliver RNAs to endosomes, we used DOTAP liposomal transfection reagent (Sigma-
Aldrich) as previously described [11,56]. In brief, 230 pmol or other various amounts of syn-
thetic RNAs were mixed with 60 μl of HBS buffer and 15 μl of DOTAP reagent and incubated
for 15 min. The RNA-DOTAP solution was then added to 1 ml HMDM or PHMDM medium,
followed by incubation of the cells for 16 h.
EV-mediated RNA delivery to endosomes
Synthetic 50-tRNAHisGUG half, 50-tRNAGluCUC half, and ssRNA40-M (80 pmol) were trans-
fected to HMDMs (9 × 106 cells) using RNAiMAX (Thermo Fisher Scientific). After 24 h, the
cells were washed with PBS and further incubated for 12 h, and the cell culture medium was
subjected to EV isolation as described above. The isolated EVs were then added to HMDMs
(1 × 106 cells), followed by incubation for 12 h, RNA extraction, and RT-qPCR quantification
of TNFα, IL-1β, and IL-12p40 mRNAs.
Regarding experiments using antisense oligonucleotides, control oligonucleotides with
scrambled sequences or antisense oligonucleotides for the 50-tRNAHisGUG half (S5 Table) were
first infused with DOTAP as described above. EVs isolated from LPS-treated HMDMs were
mixed with the DOTAP–oligonucleotides solution and then were applied to recipient
HMDMs, followed by incubation for 16 h. To eliminate possible effects of potential endotoxin
(LPS) contamination, EVs isolated from LPS-treated HMDMs were incubated with 10 mg/ml
polymyxin B (PMB) (Sigma-Aldrich) at 4˚C for 1 h prior to mixing with the DOTAP–oligonu-
cleotides solution.
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ELISA
For ELISA experiment, RNA transfection using DOTAP was performed in Opti-MEM
(Thermo Fisher Scientific), and the culture medium from 1 × 106 HMDMs or 1 × 105
PHMDMs was subjected to ELISA (R&D Systems, Minneapolis, Minnesota, USA) for quanti-
fication of TNFα and IL-1β. Their absolute amounts were calculated based on standard curves.
RNAi KD of ANG, TLR7, and TLR8
To silence the expression of ANG, TLR7, and TLR8, siRNAs designed in previous reports
[28,56,90] were synthesized by Bioland Scientific. Their sense strand sequences are 50-AAACC
UAAGAAUAAGCAAGUCAU-30, 50-GCCUUGAGGCCAACAACAUUU-30, and 50-GGUG
GUGCUUCAAUUAAUAUU-30 for ANG, TLR7, and TLR8, respectively. ON-TARGETplus
Nontargeting siRNA #2 (D-001810-02, Dharmacon, Lafayette, Colorado, USA) was used as a
negative control as previously described [28]. HMDMs were transfected with 50 nM of each
siRNA using RNAiMAX (Thermo Fisher Scientific). In simultaneous KD of TL7 and TLR8,
100 nM of the siRNA mixture for TLR7/8 (50 nM each for TLR7 and TLR8) and 100 nM of
control siRNA were used. In 60 h after transfection, LPS were added and HMDMs were fur-
ther incubated for 12 h.
TLR7 KO THP-1 cell lines
TLR7 KO THP-1 cells were generated using the CRISPR/Cas9 system at Genome Editing Insti-
tute in ChristianaCare. Two different clones, KO #1 and KO #2, were generated using gRNA1
(50-ACUUUCAGGUGUUUCCAAUG-30) and gRNA2 (50-UAGGAAACCAUCUAGCCC
CA-30), respectively. The KO cells were differentiated into HMDMs and used for transfection
of DOTAP-fused RNAs as described above. Confirmation of TLR7 depletion in the KO cells
was done using western blot analysis as described above.
Human plasma samples and RNA isolation
Human plasma samples were derived from healthy or Mtb-infected males aged 30 to 35 years
and obtained from BioIVT. For RNA isolation, 500 μl of plasma was first centrifuged at 16,060
g for 5 min, then 400 μl of supernatant was mixed with synthetic mouse piR-3 spike-in control
(20 fmol) and subjected to RNA extraction using TRIzol LS (Thermo Fisher Scientific). The
extracted RNAs were further subjected to purification using the miRNeasy Mini Kit (Qiagen,
Hilden, Germany). Based on the quantification of miR-451 and miR-23a-3p and calculation of
“miR ratio” as described earlier [91], no hemolysis was observed in any of the plasma samples.
The extracted RNA samples were subjected to quantification of 50-tRNA halves, and quantifi-
cation of piR-3 (spike-in) was used for normalization.
Supporting information
S1 Fig. NF-κB-mediated up-regulation of the expression of ANG mRNA upon surface TLR
activation. (A) HMDMs were transfected with control siRNA (siControl) or siRNA targeting
ANG (siANG) and incubated for 60 h. LPS was then added, and the cells were further cultured
for 12 h. RT-qPCR confirmed the reduction of ANG mRNA upon siANG transfection
(RPLP0: control). Averages of 3 experiments with SD values are shown (�P< 0.05, ��P< 0.01,
and ���P< 0.001; 2-tailed t test). (B) After siRNA transfection and LPS treatment of HMDMs,
RNAs isolated from the HMDMs were subjected to quantification of 50-tRNA halves. Averages
of 3 experiments with SD values are shown. (C, D) Total RNAs from HMDMs (A) or
PHMDMs (B), treated with LPS or PGN, were subjected to RT-qPCR for ANG and RPLP0
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(control) mRNAs. HMDMs/PHMDMs without treatment served as a control. Averages of 3
experiments with SD values are shown. (E) Alignment patterns of ChIP-seq reads [41] around
the ANG gene region (14q11.2: 21,152–21,162 kb) for the indicated NF-κB family proteins.
The Integrative Genomics Viewer was used for visualization. (F, G) Total RNAs from
HMDMs treated with LPS alone or LPS and JSH-23 (a NF-κB inhibitor) were subjected to RT-
qPCR for the indicated mRNAs. ANG, angiogenin; ChIP-seq, chromatin immunoprecipita-
tion and sequencing; HMDM, human monocyte-derived macrophage; LPS, lipopolysaccha-
ride; mRNA, messenger RNA; PGN, peptidoglycan; PHMDM, primary human monocyte-
derived macrophage; RT-qPCR, quantitative reverse transcription PCR; SD, standard devia-
tion; TLR, Toll-like receptor; tRNA, transfer tRNA.
(EPS)
S2 Fig. Synthetic RNAs used in the present study. (A) Synthetic RNA sequences. Guanosine
and uridine are shown in red circles. Modified nucleotides [dihydrouridine (D) and peudouri-
dine (C)] are shown in green and blue circles, respectively. (B) Indicated synthetic RNAs were
synthesized by in vitro transcription, gel-purified, and analyzed with denaturing PAGE.
(EPS)
S3 Fig. Standard curves for the quantification of miR-150 and 50-tRNAHisGUG half. Indi-
cated amounts of synthetic RNAs were subjected to stem-loop/TaqMan RT-qPCRs. Propor-
tional correlations of synthetic RNA input to the Ct were observed and used as standard
curves for estimation of the expression levels of respective RNAs. Ct, cycle threshold; RT-
qPCR, quantitative reverse transcription PCR; tRNA, transfer tRNA.
(EPS)
S4 Fig. tRNA anticodon cleavage sites for generation of 50-tRNA halves. Cleavage sites in
the tRNA anticodon loops were predicted based on the 30-terminal positions of the 50-tRNA
halves. Anticodons are shown in green. tRNA, transfer tRNA.
(EPS)
S5 Fig. Delivery of EV-50-tRNA halves into endosomal TLR7. (A, B) Florescent end-labeled,
synthetic 50-tRNAHisGUG half (A) or 50-tRNAGluCUC half (B) was transfected into HMDMs and
observed in green. Scale bar, 20 μm. (C, D) EVs produced from host HMDMs containing the
labeled 50-tRNAHisGUG half or 50-tRNAGluCUC half were isolated and applied to recipient
HMDMs. Delivery of the labeled, EV-50-tRNAHisGUG half (C) or EV-50-tRNAGluCUC half (D)
into endosomes was observed in green. Immunofluorescence staining of TLR7 is shown in
red, and DNA was counterstained with DAPI in blue. Scale bar, 100 μm. Clear co-localization
of the labeled 50-tRNA halves and TLR7 was observed. EV, extracellular vehicle; HMDM,
human monocyte-derived macrophage; TLR, Toll-like receptor; tRNA, transfer tRNA.
(TIF)
S6 Fig. Lipofectamine-mediated transfection of 50-tRNAHisGUG half has no effect on
immune response. Using RNAiMAX or Lipofectamine LTX (Thermo Fisher Scientific), the
synthetic 50-tRNAHisGUG half and ssRNA40 were transfected into HMDMs. Total RNAs from
the cells were subjected to RT-qPCR for the indicated mRNAs. Averages of 3 experiments with
SD values are shown. HMDM, human monocyte-derived macrophage; mRNA, messenger
RNA; RT-qPCR, quantitative reverse transcription PCR; SD, standard deviation; tRNA, trans-
fer tRNA.
(EPS)
S7 Fig. Activation of endosomal TLRs by various amounts of 50-tRNAHisGUG half. (A) The
indicated amounts of the synthetic 50-tRNAHisGUG half were transfected into HMDMs using
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DOTAP. Total RNAs from the cells were subjected to RT-qPCR for the indicated mRNAs. Aver-
ages of 3 experiments with SD values are shown. (B) After the RNA transfection, culture medium
was subjected to ELISA for quantification of TNFα and IL-1β. DOTAP, 1,2-dioleoyloxy-3-tri-
methylammonium-propane; HMDM, human monocyte-derived macrophage; IL, interleukin;
mRNA, messenger RNA; RT-qPCR, quantitative reverse transcription PCR; SD, standard devia-
tion; TLR, Toll-like receptor; TNFα, tumor necrosis factor α; tRNA, transfer tRNA.
(EPS)
S8 Fig. siRNA-mediated KD of TLR7 and TLR8 in HMDMs. (A) HMDMs were transfected
with control siRNA (siControl) or siRNA targeting TLR7 (siTLR7) or TLR8 (siTLR8). To con-
firm the reduction of the targeted mRNA, total RNAs from the cells were subjected to RT-
qPCR for TLR7 and TLR8 mRNAs (RPLP0: control). (B) Double KDs of TLR7 and TLR8 were
performed by simultaneously transfecting both siTLR7 and siTLR8, and reduction of the both
mRNAs was confirmed by RT-qPCR. (C) In HMDMs, the expression of both TLR7 and TLR8
was silenced by siRNAs and then DOTAP-fused 50-tRNAHisGUG half or ssRNA40-M was trans-
fected. Total RNAs from the cells were subjected to RT-qPCR for the indicated mRNAs.
DOTAP, 1,2-dioleoyloxy-3-trimethylammonium-propane; HMDM, human monocyte-
derived macrophage; KD, knockdown; mRNA, messenger RNA; RT-qPCR, quantitative
reverse transcription PCR; TLR, Toll-like receptor.
(EPS)
S9 Fig. Detection of tRNA halves in EVs isolated from human plasma. (A) EVs were iso-
lated from human plasma and were analyzed by NTA. Representative size distribution profile
is shown. (B) Isolated EVs were treated with RNase A and/or Triton X-100 and then subjected
to TaqMan RT-qPCR for quantification of 50-tRNA halves. Averages of 3 experiments with SD
values are shown (�P< 0.05, ��P< 0.01, and ���P< 0.001; 2-tailed t test). (C) Human plasma
samples (batches #2–4) were treated with RNase A and/or Triton X-100 and then subjected to
TaqMan RT-qPCR for quantification of 50-tRNA halves. Averages of 3 experiments with SD
values are shown. EV, extracellular vehicle; NTA, nanoparticle tracking analysis; RT-qPCR,
quantitative reverse transcription PCR; SD, standard deviation; tRNA, transfer tRNA.
(EPS)
S1 Movie. NTA analysis from control (PBS) sample. NTA, nanoparticle tracking analysis.
(MP4)
S2 Movie. NTA analysis from EV sample. EV, extracellular vehicle; NTA, nanoparticle track-
ing analysis.
(MP4)
S1 Table. Read numbers of sequence libraries.
(PDF)
S2 Table. Sequences of TaqMan probes and primers for TaqMan RT-qPCR. RT-qPCR,
quantitative reverse transcription PCR.
(PDF)
S3 Table. Sequences of primers for stem-loop RT-qPCR. RT-qPCR, quantitative reverse
transcription PCR.
(PDF)
S4 Table. Sequences of primers for standard RT-qPCR. RT-qPCR, quantitative reverse tran-
scription PCR.
(PDF)
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S5 Table. Sequences of synthetic RNAs/DNAs.
(PDF)
S6 Table. Sequences of primers for the synthesis of dsDNA templates.
(PDF)
S1 Raw Image. Original gel images contained in this manuscript, related to Figs 1D, 2A,
3A and 3B.
(TIF)
S2 Raw Image. Original gel images contained in this manuscript, related to Fig 6B and S2B
Fig.
(TIF)
S1 Data. Numerical data underlying Fig 1A–1C, 1E and 1F; Fig 2B and 2D; Fig 3C–3G; Fig
5A–5F; Fig 6A and 6C; Fig 7A–7C; Fig 8A and 8B; and S1A–S1D and S1F and S1G Fig; S3
Fig; S6 Fig; S7 Fig; S8A–S8C Fig and S9A–S9C Fig.
(XLSX)
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